Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of rVIIa-FP (CSL689) in Congenital Factor VII Deficiency
NCT02470871Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Jul 2015
- Primary completion
- Jul 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of CSL689 in congenital factor VII deficiency (2 arms), sponsored by CSL Limited. Primary endpoints: Terminal half-life of plasma FVIIa activity up to 48 hours, Maximum observed plasma FVIIa activity up to 48 hours and 1 more. Started Jul 2015; status: completed.
02
Drugs
CSL689
03
Conditions
congenital factor VII deficiency
Beyond the preview
Go deeper on NCT02470871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470871.